| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8630129 | Diabetes Research and Clinical Practice | 2018 | 20 Pages |
Abstract
Vildagliptin and gliclazide MR similarly reduced the MAGE in women with T2DM after 24â¯weeks of treatment. Further studies are required to attest differences between vildagliptin and gliclazide MR regarding glycemic variability.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Andre Gustavo Daher Vianna, Claudio Silva Lacerda, Luciana Muniz Pechmann, Michelle Garcia Polesel, Emerson Cestari Marino, Jose Rocha Faria-Neto,